...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pediatric drugs >CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia
【24h】

CD19 CAR T Cells for the Treatment of Pediatric Pre-B Cell Acute Lymphoblastic Leukemia

机译：CD19 CAR T细胞用于治疗儿科前B细胞急性淋巴细胞白血病

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The development of cluster of differentiation (CD)-19-targeted chimeric antigen receptor (CAR) T cells for the treatment of pre-B-cell acute lymphoblastic leukemia (B-ALL) is an exciting new advancement in the field of pediatric oncology. Tisagenlecleucel and axicabtagene ciloleucel are the first US FDA-approved CD19-targeted CAR T cells. While various different CD19 CAR T cells are in development, tisagenlecleucel is the only CAR T cell approved for pediatric patients. The multicenter phase II trial that led to the approval of tisagenlecleucel demonstrated excellent responses in individuals with highly refractory disease. Other high-risk groups of patients with B-ALL who experience poor outcomes with standard therapy may also benefit from treatment with tisagenlecleucel. After receiving CAR T cells, patients must be closely monitored for unique toxicities, including cytokine release syndrome, neurotoxicity, and B-cell aplasia. The management of patients with relapsed or refractory disease after administration of CD19 CAR T cells can be challenging, and treatment options vary according to the characteristics of the disease present at relapse. In the many patients who experience a complete response, CAR T cells can lead to a durable remission. This review describes the current design and manufacturing of CAR T cells. Data in the selection and management of pediatric patients are highlighted, as are areas where further studies are needed.
机译：用于治疗前B细胞急性淋巴细胞白血病（B-All）的分化簇（CD）-19靶向嵌合抗原受体（CAR）T细胞的发展是小儿肿瘤领域的激动人心的新进步。 Tisagenlecleucel和Axicabtagene Ciloleucel是美国FDA批准的CD19靶向汽车T细胞。虽然各种不同的CD19汽车T细胞正在开发，但Tisagenlecleucel是唯一用于儿科患者的汽车T细胞。导致Tisagenlecleule批准的多中心第二期审判表现出具有高难治性疾病的个体的优异反应。其他高风险群体的B-all与标准治疗的结果差异也可能受益于与Tisagenleclecel的治疗。在接收到Car T细胞后，必须密切监测患者以针对独特的毒性，包括细胞因子释放综合征，神经毒性和B细胞APLASIA。在给予CD19 Car T细胞后复发或难治性疾病的患者的管理可能是挑战性的，并且治疗期权根据复发存在的疾病的特征而变化。在许多经历完全反应的患者中，汽车T细胞可能导致耐用的缓解。该综述描述了汽车T细胞的当前设计和制造。突出了儿科患者的选择和管理中的数据，也是需要进一步研究的领域。

著录项

  • 来源
    《Pediatric drugs》 |2020年第1期|共11页
  • 作者

    Pacenta Holly L.; Laetsch Theodore W.; John Samuel;

  • 作者单位

    Univ Texas Southwestern Med Ctr Dallas Div Pediat Hematol Oncol 5323 Harry Hines Blvd Dallas TX;

    Univ Texas Southwestern Med Ctr Dallas Div Pediat Hematol Oncol 5323 Harry Hines Blvd Dallas TX;

    Univ Texas Southwestern Med Ctr Dallas Div Pediat Hematol Oncol 5323 Harry Hines Blvd Dallas TX;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号